%Responders to RITUXIMAB in the cohort (WORLD):
by Thymidine Incorporation (95% CI): %20.4225 (16.6667,24.4131)
by IL-2 ELISpot (95% CI): %5.3991 (3.2864,7.7465)
by Combined Thymidine Incorporation & IL-2 ELISpot (95% CI): %5.3991 (3.2864,7.7465)
--
%Similarity between Thymidine Incorporation & IL-2 ELISpot predictions (95% CI): %84.8732 (81.6099,88.1366)
